Combination approaches will almost certainly be required to generate durable control of HIV
in the absence of antiretroviral therapy (a "remission"). In this study, 20 individuals will
receive a combination regimen administered during ART and then undergo an analytic treatment
interruption (ATI).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
amfAR, The Foundation for AIDS Research GeoVax, Inc. Ichor Medical Systems International AIDS Vaccine Initiative Mologen AG National Institute of Allergy and Infectious Diseases (NIAID) NIH Vaccine Research Center Rockefeller University